StocksMediumUpdated×2•Originally published 1 August 2026•Updated 2 August 2026•
1 min read
Beta Bionics beats Q2 estimates on revenue and narrower loss
Key Facts
1Beta Bionics reported Q2 2026 EPS of -$0.36, beating estimates by $0.20.
2Beta Bionics reported Q2 2026 revenue of $32.01 million, up 37.76% year over year and $533.03K above expectations.
As markets assess healthcare companies’ ability to translate sales growth into improving profitability, Beta Bionics reported quarterly results that exceeded estimates. According to reports, the company posted a Q2 2026 loss of $0.36 per share, beating estimates by $0.20. Revenue reached about $32.01 million, rising 37.76% year over year and exceeding expectations by $533.03 thousand.
The second-quarter results provide a positive signal on Beta Bionics’ revenue growth, while its quarterly loss remains a key consideration for the profitability outlook. According to reports, the revenue and earnings beats were disclosed alongside the company’s earnings-call presentation.